On May 10, the National Development and Reform Commission issued the "14th Five-Year Plan for Bio-economic Development" (hereinafter referred to as the "Plan"), which is also the first top-level design in China's bio-economic field.

 

The plan emphasizes the need to vigorously develop advanced diagnostic technologies and products such as molecular diagnosis, chemiluminescence, immunodiagnosis, and point-of-care testing, accelerate the development of high-throughput gene sequencing technology, and strengthen the research and development of biological detection technologies such as microfluidics and high sensitivity.

 

The total bioeconomy aims to reach 22 trillion CNY in 2025

 

Bai Jingyu, director of the Innovation-Driven Development Center of the National Development and Reform Commission, once said: Through 5 years of hard work, we will strive to reach 22 trillion CNY in my country's total bioeconomy by 2025, of which the total amount of core industries exceeds 75,000. 100 million yuan, making the bioeconomy a strong driving force for the high-quality development of my country's economy.

 

Improve the ability to respond to major severe infectious diseases

 

One of the highlights of the "14th Five-Year Plan for Bioeconomic Development" is that it proposes to adapt to the new trend of "treatment-centered" to "health-centered".

 

Focus on improving the people's health protection capabilities, focusing on drugs, vaccines, advanced diagnosis and treatment technologies and equipment, biomedical materials, precision medicine, inspection and testing, and biological health care, etc. Develop high-end products and ensure the equipment supply chain.

 

Vigorously develop content related to IVD

 

Frist of all, focus on the early prevention of diseases, promote the deep integration of advanced technologies such as genetic testing and biological genetics with disease prevention, and carry out early screening of major diseases such as genetic diseases, birth defects, tumors, cardiovascular diseases, and metabolic diseases

 

Second, improve disease diagnosis ability. Promote the integration and innovation of biotechnology and cutting-edge technologies such as precision machinery, new materials, and additive manufacturing

 

Third, improve clinical medical level, encourage the development of original drugs for chronic diseases, tumors, neurodegenerative diseases and other major diseases and rare diseases.

 

Increase the number of third-party service agencies in the biological field

 

Market entities in the field of bioeconomy are developing vigorously, the number of companies with annual operating income of more than 10 billion CNY should increase significantly, and innovative and entrepreneurial enterprises grown rapidly.

 

Inspection and testing should improve the original innovation ability

 

In line with the new trend of "treatment-centered" to "health-centered", develop biomedicine oriented to people's life and health, and meet people's new expectations for more security in life and health.

 

Focus on improving the people's health protection capabilities, focusing on medicines, vaccines, advanced diagnosis and treatment technologies and equipment, biomedical materials, precision medicine, inspection and testing, and biological health care.

 

Strengthen the research and development of biological detection technologies such as microfluidics

 

The "Plan" gives priority to the application of bio-innovative technologies in the fields of medicine, medical care, and health: "targeting clinical medicine and health management, new drug discovery, brain science, synthetic biology, biological breeding, prevention and control of emerging infectious diseases and biosafety and other cutting-edge fields, implement major national science and technology projects and R&D plans”

 

Influential units take the lead in establishing a production-use consortium

 

"Develop and strengthen new innovative forces. In cutting-edge fields such as high-end scientific research instruments, medical equipment, new drug creation, biological manufacturing, biological breeding, and biomass energy, support influential user units to lead the establishment of production-use consortia and cooperate with production enterprises. Carry out technological innovation and demonstration verification of biological products and build a virtuous cycle development mechanism of "application demonstration-feedback improvement-level improvement-radiation promotion".

 

Encourage bio-enterprises to establish overseas R&D centers

 

Encourage domestic scientific research institutions in the biological field to take the initiative to initiate and participate in international major scientific projects, and actively participate in the formulation of international rules and standards in the fields of biological resource protection and utilization, medicine and health, and biological manufacturing.

 

Optimizing the review process for innovative medical devices

The "Plan" refers to further improving the principle of priority approval of drugs and medical devices to encourage simultaneous domestic and overseas research and development applications for new drugs. Fully implement the drug marketing license holder system and optimize the license holder reform procedures and requirements. Accelerate the promotion of the medical device registrant system, improve the management of entrusted production, and optimize the allocation of innovation resources.